What’s Trending: ADCs: Pipelines, Products & CDMO Growth 

Sponsored by Lonza AG

Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments, and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights.  

Gaurav Chaudhary, CEO, Roots Analysis

DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance. ICYMI, other recent episodes include:  

“Drug Launches & Approvals in 2025: The Blockbuster Contenders” featuring Matthew Arnold, Principal Analyst and Content Strategist, Clarivate  

“CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?” featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice;  

“Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?” featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)  

“Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?” featuring Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate  

“Biomanufacturing: How are Industry Capacity & Supply Chains Trending?” featuring Eric Langer, MBA, Managing Partner & President, BioPlan Associates, and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates;   

“Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?”  featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of  L.E.K.’s Pharmaceutical Contract Services Practice; and   

“Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead” featuring Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP.  

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

You May Also Like

What Tops the Industry’s Sustainability Agenda for 2026?

By
As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology…

2026 Outlook: CDMO Market for Injectables

By
Sponsored by Lonza AG In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian…

2026: Drugs To Watch: The Year Ahead

By
Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist,…

2025: The Bio/Pharma Industry’s Year in Review

By
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course…